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Abstract: The NK cells functions are finely tuned by several kinds of inhibitory and activating 
receptors, whose pattern of expression characterizes different NK subpopulations and varies with the 
cell activation status. MicroRNAs have an important role in tightly regulating the expression of NK 
receptors and, analogously, the expression of their ligands in target cells. The relevance of the 
microRNA-mediated control is highlighted by the dysregulation of these pathways observed in 
cancer and virus-infected cells. Here we review our current knowledge of the microRNAs involved 
in the regulation of NK receptors, as well as that of the corresponding cellular ligands. 
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1. Introduction  
Natural Killer (NK) cells are innate lymphoid cells endowed with several effector and 
regulatory functions, including cytotoxic activity against virus infected and tumor-transformed cells. 
Although there is a growing knowledge of the phenotypic heterogeneity of the NK cell population [1], 









 cells, which have different function and tissue distribution. CD56
bright
 NK cells, which 
release large amount of soluble factors in response to pro-inflammatory cytokines, are poorly 
represented in peripheral blood, while largely populating secondary lymphoid organs. Conversely, 
CD56
dim
 cells, which are highly cytotoxic effectors, represent the largest percentage of circulating 
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NK cells.  
The NK cell functions are finely regulated by a variety of germline-encoded inhibitory and 
activating receptors and by different cytokines, produced in the early or in the late phase of immune 
responses. All these cytokines other than potentiate NK cell responsiveness towards transformed 
cellular targets, stimulate the production of chemokines and cytokines (IFN-γ, TNF-α) crucial for 
shaping both innate and adaptive immunity [1,2]. 
The main inhibitory NK receptors include: Killer-cell immunoglobulin-like receptors (KIRs), 
CD94/NKG2A and LILRB1, MHC class I-specific receptors that physiologically maintain 
self-tolerance; PD-1, TIM-3 and LAG-3 that belong to the immune checkpoint family, inhibitory 
pathways that are induced/up-regulated during immune responses and limit the duration and 
amplitude of the immune responses, thus minimizing tissue damage. Activating signals are mediated 
by a plethora of activating receptors and co-receptor including NKp46, NKp30 and NKp44 
(collectively termed Natural Cytotoxicity Receptors, NCR), NKG2D and DNAM-1. The activating 
receptors recognize non-MHC ligands up-regulated or de novo expressed by cells upon cellular stress, 
tumor transformation or viral infection. The modality of NK cell activation, well depicted by the 
rheostat model [3,4], depends on the cytokine milieu as well as on the presence/absence and surface 
densities of the different ligands on neighboring healthy or altered cells.  
Different mechanisms regulate the expression of receptors, on effector NK cells, or ligands on 
potential targets. Among these, microRNA-mediated mechanisms that regulate gene expression at 
the post-transcriptional level. MicroRNA (miRNAs) are small RNAs, processed from stem-loop 
regions of longer RNA transcripts, which can interact with the 3’-Untranslated Region (3’-UTR) of 
target mRNAs via sequence complementarity, thus down-regulating gene expression through 
translation repression and/or mRNA degradation [5]. The importance of this kind of regulation is 
underlined by the fact that tumors and viruses evolved mechanisms to negatively affect NK activity 
acting through these pathways.  
This review synthetically describes the current knowledge of miRNAs targeting molecules 
fundamental for the NK cell effector functions and trafficking. 
2. NK cell receptors and miRNAs 
Several miRNAs have been described that target different NK receptor pathways. These include 
activating receptors (NKG2D), the DAP12 signaling molecule, inhibitory receptors (KLRG1), 
immune checkpoint receptors (TIM-3, PD-1 and CTLA-4), chemokine and cytokine receptors 
(CX3CR1, IL-2Rγ). Interestingly, TGF-β1, an immune-modulatory cytokine highly produced and 
activated in the tumor microenvironment [6], has been shown to hamper NK cells activity 
down-regulating different receptors via distinct miRNA pathways (Figure 1). 
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Figure 1. TGF-β1 modifies the receptors expression in human NK cells. The TGF-β1 
contained in the tumor microenvironment reduces the expression of NKG2D, 
DAP12/NKp44 and CX3CR1 in NK cells via different miRNA-mediated pathways. The 
involvement of miRNAs in the TGF-β1-mediated up-regulation of CXCR4 and CXCR3 [9] 
or down-regulation of NKp30 [8] and DNAM-1 [91] remains to be determined. 
2.1. NKG2D 
NKG2D (CD314) is a C-type lectin-like receptor expressed on NK and CD8
+
 T cells. It is an 
activating receptor able to detect and promote the elimination of damaged, transformed, and 
pathogen-infected cells by recognizing stress-inducible ligands belonging to the MIC (MICA and 
MICB) and ULBP (ULBP1–6) families in humans [7]. In vitro studies showed that the surface 
expression of NKp30 and NKG2D is significantly down-regulated by conditioning NK cells with 
TGF-β1 or TGF-β2 [8,9]. Moreover, subsequent studies highlighted the presence in vivo of 
NKG2D
low
 NK cells in cancer patients, ascribable to TGF-βactivity. One mechanism responsible for 
the TGF-β-mediated NKG2D down-regulation has been associated to the impairment of 
transcriptional and translational level of DAP10, the signaling subunit associated with human 
NKG2D [10]. Another mechanism has been showed by Espinoza et al. [11] who reported that 
TGF-β1 causes an increase of miR-1245 in NK cells. Overexpression of miR-1245 induced a 
down-regulation of NKG2D at the cell surface level, but had no effect on other activating receptors 
such as NKp30, NKp44 and NKp46. Moreover, NK cells overexpressing miR-1245 had lower 
cytotoxicity against target cells expressing NKG2D ligands. MiR-1245 was shown to directly target 
and down-regulate the NKG2D mRNA. 
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2.2. DAP12 
DAP12 (DNAX activating protein of 12 kDa) (also termed killer cell activating 
receptor-associated protein, KARAP) is a transmembrane protein containing an immune 
tyrosine-based activation motif (ITAM) in its cytoplasmic domain [12]. DAP12 is a fundamental 
signaling molecule that mediates a broad array of biological functions by associating with different 
activating receptors expressed in cells of lymphoid and myeloid lineage [12]. These receptors include 
the activating isoform of KIRs, CD94/NKG2C, and NKp44, the latter being expressed by NK cells 
upon activation. Donatelli et al. [13] reported that TGF-1 down-regulates the DAP12 level in NK 
cells. MiR-183, which was up-regulated by TGF-1, was shown to directly target DAP12 mRNA. 
NK cells overexpressing miR-183 had reduced DAP12 (both mRNA and protein) as well as 
decreased NKp44 surface levels. NK92 cells transduced with miR-183 were less efficient in killing 
Raji cells (which do not express NKG2D ligands) with respect to control lentiviral transduced cells. 
Interestingly, NK cells infiltrating lung cancers were shown to have a diminished DAP12 expression. 
2.3. KLRG1 
KLRG1 is a C-type lectin-like inhibitory receptor, containing an immune tyrosine-based 
inhibitory motif (ITIM), which binds to members of the cadherin family leading to inhibition of NK 
and T cell function. It is predominantly expressed by NK cells with a mature phenotype [14] and it is 
strongly induced by viral and other infections [15]. Cipolla et al. [16] reported that miR-584-5p 
targets KLRG1 and that overexpression of miR-584-5p in peripheral blood mononuclear cells 
(PBMC) causes a decrease of KLRG1 mRNA expression. Interestingly, a 3’-UTR KLRG1 
polymorphism, rs1805672, associated to the autoimmune disease Pemphigus foliaceus, abolishes the 
binding of the miRNA, thus causing the loss of the miRNA-mediated control of KLRG1 expression. 
Authors suggested a link between the loss of the miRNA-target interaction and predisposition to the 
autoimmune disease. 
2.4. TIM-3 
TIM-3 belongs to the T cell immunoglobulin and mucin domain (TIM) family. It is expressed 
on the surface of several immune cells, including NK cells. Upon activation by the C-type lectin 
galectin-9 ligand, TIM-3 functions as an inhibitory receptor on NK cells by reducing their 
cytotoxicity and cytokine production [17]. Cheng et al. [18] reported that TIM-3 and T-bet 
expression in NK cells from chronically HCV-infected patients is up-regulated compared to NK from 
healthy controls, while miR-155 is down-regulated. The opposite regulation of TIM-3/T-bet and 
miR-155 was recapitulated in vitro by incubating primary NK cells or the NK92 cell line with Huh-7 
hepatocytes expressing HCV. MiR-155 transfected in NK92 cells reduced TIM-3 and T-bet and 
enhanced IFN-γ expression. Authors suggest that TIM-3 expression is indirectly regulated by 
miR-155. 
2.5. PD-1 
PD-1 is an immune checkpoint receptor evolutionary related to the CD28 family. It recognizes 
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two cellular ligands, PD-L1 and PD-L2, and can be expressed on several cell types including T, B, 







 NK cells, whose antitumor activity can be partially restored 
in vitro by antibodies disrupting the PD-1/PD-Ls interactions [19]. Timing in the expression of PD-1 
is in line with the PD-1-dependent regulatory activity, which occurs in the later phases of the 
immune response [20]. To date, no miRNAs modulating PD-1 have been described in NK cells. 
Nevertheless, miR-4717, regulating only PD-1 variants containing a specific polymorphism in the 
3’-UTR, has been described in total lymphocytes [21]. Moreover, miR-138 has been reported to 
modulate CTLA-4 and PD-1 expression in mouse and human CD4
+
 T cells [22], and miR-28 has 
been described to regulate PD-1 in mouse CD4
+
 T cells [23]. 
2.6. CTLA-4 
CTLA-4 (CD152) is an immune checkpoint receptor binding the CD80 and CD86 ligands with 
higher affinity than CD28. It is expressed in Treg and activated T cells, while its expression in NK 
cells has been detected in mouse, but not in human [24]. CTLA-4 is targeted by miR-155, and in 
stimulated naive TH cells transfection with the miR-155 precursor down-regulates CTLA-4 
expression [25]. Moreover, as for PD-1, CTLA-4 is regulated by miR-138 in mouse and human 
CD4
+
 T cells [22]. 
2.7. CX3CR1 
CX3CR1 is a chemokine receptor expressed by different immune cell types, including 
monocytes, dendritic cells (DCs), T, and NK lymphocytes, which binds CX3CL1 (also known as 
fractalkine). CX3CR1, with other chemokine receptors, drives, at steady state, NK cell localization in 
peripheral tissues, and promotes their migration under inflammatory conditions [26]. Moreover, it 
has been shown that CX3CR1, CXCR4 and S1P5 regulate NK cells homing and migration from the 
bone marrow (BM) [27,28]. It has been demonstrated that the surface expression of CX3CR1 was 
down-regulated in NK cells co-cultured with SH-SY5Y neuroblastoma (NB) cells under trans-well 
conditions. Notably, CX3CR1 expression was reduced in NK cells from NB patients compared with 
healthy controls [9]. TGF-β1 released by NB cells has been shown to be responsible for the observed 
CX3CR1 down-regulation, as also confirmed in vitro using recombinant TGF-β1. Looking for the 
mechanisms involved, TGF-β1 was found to determine a significant increase of miR-27a-5p, which 
targeted the CX3CR1 mRNA in NK cells [29]. Up-regulation of miR-27a-5p was due to the 
TGF-β1-dependent up-regulation of miR-23a-27a-24-2 cluster, which encodes, among others, 
miR-27a-5p. As expected, inhibition of miR-27a-5p expression in NK cells caused an up-regulation 
of the CX3CR1 mRNA. Conversely, a reduction of CX3CR1 surface expression was observed in 
CX3CR1-expressing HEK293T cells following their treatment with miR-27a-5p mimic. In agreement 
with the original findings [9], NK cells cultured in the presence of SH-SY5Y NB cells exhibited a 
significant up-regulation of miR-27a-5p and down-regulation of CX3CR1 mRNA [29].  
2.8. IL-2Rγ 
IL-2Rγ is a transmembrane protein belonging to the cytokine receptor gene superfamily. It is the 
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γ component of multiple cytokine receptors, including those for IL-2, -4, -7, -9, -15, and -21, which 
are expressed on the surface of lymphocytes and other hematopoietic cells. Lack of IL2Rγ due to 
mutations of the encoding gene is responsible for X-linked severe combined immunodeficiency 
(X-SCID), a cellular and humoral immunodeficiency with a near-complete absence of NK and T 
cells and nonfunctional B cells [30]. Yun et al. [31] reported that miR-583 targets IL-2Rγ. 
Differentiating NK cells transfected with miR-583 mimics showed a decreased surface expression of 
IL-2Rγ and defective differentiation. In particular, the miR-583 overexpressing NK cells showed 
decreased NKG2D, NKp30 and NKp46 expression and reduced capacity to kill target cells and to 
produce IFN-γ [31]. 
3. NK receptor ligands and miRNAs 
A number of miRNAs have been identified as regulators of ligands of NK cell receptors. 
Targeted molecules include ligands for MHC class I-specific (HLA-G, HLA-C, HLA-E) and non- 
specific (MICA, MICB, ULBPs) receptors, as well as the immune checkpoint ligands PD-L1, B7-H3, 
CD80 and CD86. In cancer cells modification of miRNA expression may represent a common 
mechanism of escape from the NK-mediated immune surveillance (Figure 2). 
 
Figure 2. Altered ligands expression in tumor cells. Cancer cells can hamper NK 
cytotoxicity by up- or down-regulating a number of miRNAs, which reduce the 
expression of ligands of activating receptors or increase that of inhibitory ones, 
respectively. The latter includes the immune checkpoint ligands PD-L1 and B7-H3. 
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3.1. NKG2D ligands 
NKG2D ligands MICA, MICB, and ULBPs can be regulated by several miRNAs, of cellular or 
viral origin [32] that are potentially able to protect cancer cells and virus infected cells from NK cell 
cytotoxicity [7,32,33]. Stern-Ginossar et al. [34] reported 7 miRNAs regulating MICA and MICB 
expression (miRNAs miR-17-5p, miR-20a-5p, miR-93-5p, miR106b-5p, miR-372, miR373-3p, 
miR-520d-3p). Overexpression of these miRNAs in vitro and in vivo resulted in down-regulation of 
MICA and MICB expression and in lower susceptibility to NKG2D-dependent killing by human NK 
cells. On the other hand, three different viral miRNAs (miR-UL112, miR-BART2.5p and 
miR-K12-7), all derived from herpesviridae, targeted MICB, while a miRNA from polyoma viruses 
JCV and BKV targeted ULBP3 [32,33]. Two miRNAs (miR-376a and miR-433) were shown to 
regulate MICB and to decrease NK-mediated cytotoxicity against colon carcinoma cells [35]. 
MiR-34a and miR-34c were reported to target ULBP2 and, when overexpressed in a melanoma cell 
line, down-regulated its expression at the protein level. Moreover, miR-34c transfected melanoma 
cells displayed reduced susceptibility to NK cells cytotoxicity [36]. Other miRNAs (miR-10b, 
miR-519-3p, miR-20a, miR-93, miR-106b, miR302c, miR-520c), which were found overexpressed 
in various tumors, have been shown to down-regulate MICA, MICB and ULBP2, and, consequently, 
to reduce the NK cell-mediated killing of target cells [37–42].  
3.2. HLA-G 
HLA-G is a non-classical HLA class Ib molecule, expressed mainly in the placental trophoblasts, 
where is thought to provide immune protection to the embryo from the decidual NK cells, the major 
lymphocyte population at the fetal-maternal interface. HLA-G is also expressed by tumors and 
virus-infected cells [43]. HLA-G is recognized by LILRB1 and KIR2DL4 inhibitory receptors on 
human NK cells [44] and its soluble form has been described to regulate the chemokine receptor 
repertoire [45]. Several miRNAs down-regulate HLA-G expression: miR-148a, miR-152 (belonging 
to the same miRNA family), miR-133a, miR-548q, miR-628-5p and miR-365 [44,46–48]. An inverse 
correlation was reported between miR-628-5p and HLA-G in primary renal cell carcinoma tumors 
and cell lines [49]. In the case of miR-148a, miR-152 and miR-548q, it has been experimentally 
shown that they induce in target cells HLA-G down-regulation and increased susceptibility to the 
cytolytic activity of LILRB1
+
 NK cells [44,47,49]. The long noncoding RNA HOTAIR has been 
shown to bind miR-148a in cervical cancer [50] and miR-152 in gastric cancer cells [51], thus 
up-regulating HLA-G. TGF-β1 has been reported to cause a down-regulation of miR-152 inducing 
an up-regulation of HLA-G in gastric cancer cell lines [52]. 
3.3. HLA-C 
HLA-C are classical HLA class I molecules recognized by inhibitory KIRs. In particular, 
KIR2DL1 binds C2 allotypes characterized by a lysine in position 80, whereas KIR2DL2 and 
KIR2DL3 recognize C1 allotypes sharing an asparagine in position 80 [53]. Interestingly, miR-148a 
is able to bind not only HLA-G, but also HLA-C. Kulkarni et al. [54] reported that a polymophism in 
the HLA-C 3’-UTR regulates binding capability of miR-148a to its target site, resulting in relatively 
low HLA-C surface expression of alleles that bind this miRNA and high expression of HLA-C 
105 
AIMS Allergy and Immunology  Volume 2, Issue 2, 98–112. 
alleles that escape post-transcriptional regulation. 
3.4. HLA-E 
The non-classical HLA-E binds a restricted subset of peptides encoded by the leader sequence 
of other class I molecules. It is recognized by the inhibitory CD94/NKG2A and activating 
CD94/NKG2C heterodimeric receptors, both expressed by T cells and NK cells [55]. The human 
cytomegalovirus [HCMV] encodes UL40, a peptide stabilizing HLA-E and driving the proliferation 
of CD94/NKG2C
+
 NK cells [56]. Interestingly, Nachmani et al. [57] showed that the short form of 
the RNA-editing enzyme ADAR1 induced editing of miR-376a in HCMV
+
 cells. Edited miR-376a 
down-regulated HLA-E expression rendering HCMV infected cells susceptible to elimination by NK 
CD94/NKG2A
+
 NK cells. 
3.5. PD-L1 
PD-L1 and PD-L2 are the two ligands of the PD-1 inhibitory receptor, which is expressed by 
activated NK and T cells [58,59]. Under physiological conditions, the PD-1/PD-Ls interactions 
control the duration and amplitude of immune responses, preventing autoimmune reactions. In 
cancer cells the expression of PD-Ls plays a crucial role in immune evasion. Several miRNAs 
regulating PD-L1 have been described, suggesting a tight control of its expression. In cancer cells 
PD-L1 expression is accompanied by miRNAs down-regulation [60–62]. MiR-513 has been the first 
miRNA reported to regulate PD-L1 and its inhibition in cholangiocytes induced PD-L1 protein 
expression [63]. In acute myeloid leukemia samples an inverse correlation was reported between 
miR-34 and PD-L1 expression and miR-34 was found to regulate PD-L1 expression in leukemia cell 
lines [64]. An inverse correlation was also reported between miR-200 and PD-L1 expression in lung 
adenocarcinoma samples. MiR-200 suppressed PD-L1 expression in murine and human 
mesenchymal lung cancer cell lines, while its down-regulation increased PD-L1 expression causing 
CD8
+
 T cells immune suppression [65]. MiR-138-5p was also found to target PD-L1. An inverse 
correlation was reported between miR-138-5p and PD-L1 expression in human colorectal cancer 
(CRC) samples and miR-138-5p overexpression suppressed CRC cell tumorigenicity [66]. Other 
miRNAs have been described as regulators of PD-L1 in various cancer cells, miR-15a, miR-15b and 
miR-16 in malignant pleural mesothelioma cell lines [67], miR-17-5p in metastatic melanoma [68], 
miR-142-5p in a pancreatic cancer cell line [69], miR-140 in non-small cell lung cancer (NSCLC) 
cell lines [70]. MiR-424(322) regulated PD-L1 and CD80 in ovarian cancer and high levels of this 
miRNA correlated with increased progression-free survival of patients [71]. Expression of miR-152 
was low in gastric carcinoma compared to controls, and miR-152 mimics inhibited PD-L1 expression 
in gastric cancer cell lines with increased T cell proliferation and function [72]. MiR-324-5p and 
miR-338-5p targeted PD-L1 and dendritic cells expressing these miRNAs displayed reduced surface 
expression of PD-L1 [73]. 
3.6. B7-H3 
B7-H3, a member of the B7 superfamily [74,75], is the orphan ligand of an inhibitory receptor 
expressed by human NK and CD8
+ 
T cells [74,76]. B7-H3 is considered as a new member of the 
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immune checkpoint family [77]. Indeed, it has been shown to inhibit cytotoxicity and protect 
neuroblastoma (NB) (and other tumor cells) from NK cell-mediated lysis [74,76]. B7-H3 also 
promotes tumor invasiveness [78]. In line with these pro-tumoral properties, high B7-H3 expression 
correlates with poor prognosis in several tumor histotypes [78,79]. B7-H3 expression is regulated by 
several miRNAs. Xu et al. [80] reported that miR-29a, b, c are down-regulated in several B7-H3 
expressing tumor tissues compared to normal tissues. MiR-29a targets B7-H3 in neuroblastoma cell 
lines [80] and down-regulation of miR-29a in central nervous system NB metastasis is associated 
with up-regulation of different molecules, including B7-H3 [81]. MiR-29c expression was inversely 
correlated to B7-H3 expression in melanoma [82] and was reported to target B7-H3 in breast cancer, 
where miR-29c expression correlated with increased survival [83]. Another miRNA targeting B7-H3 
is represented by miR-187. MiR-187 was down-regulated in clear cell renal cell carcinoma [ccRCC] 
compared to normal tissues. Overexpression of miR-187 (as well as silencing of B7-H3) decreased 
cell migration in ccRCC cell lines [84]. Interestingly, in CRC cell lines, miR-143 was 
down-regulated by TGF-β1, thus causing the up-regulation of both its targets B7-H3 and B7-H4 and 
leading to tumor immune evasion [85]. MiR-124 targeted B7-H3 in osteosarcoma [OS] cells and 
inhibited their growth and invasive ability. Moreover, miR-124 was down-regulated in OS clinical 
specimens, with an inverse correlation between miR-124 and B7-H3 protein expression [86].  
3.7. CD80 and CD86 
The expression of CD80 and CD86, CTLA-4 ligands, can be modulated by miRNAs. Besides 
miR-424(322) that regulates both PD-L1 and CD80 (see above) [71], miR-134 has been shown to 
bind CD86 mRNA suppressing its expression. Transfection of miR-134 in a melanoma cell line 
caused reduction of CD86 at the mRNA and protein level [87]. 
4. Conclusion 
What clearly emerges from the recent literature on the regulation of NK receptors and ligands 
expression is a central role of miRNAs in the maintenance of a delicate equilibrium that can be 
heavily perturbed by tumor transformation or viral infection.  
To escape NK cell immunosurveillance, tumor and virus infected cells evolved mechanisms to 
deregulate the expression of genes coding for molecules important for effector/target interactions [88]. 
These mechanisms often use the miRNA machinery. Pathological cells can affect NK-mediated 
recognition by up- or down-regulating miRNA targeting activating or inhibitory receptor ligands, 
respectively. Tumor cells can also act on NK cells by producing immunomodulatory factors, such as 
TGF-β1 that, influencing the expression of different receptors via distinct miRNA-pathways, realizes 
a combined inhibitory action. Other mechanisms can add levels of complexity to the action of the 
miRNA machinery, as the long noncoding RNAs sequestering miRNAs or the polymorphisms in the 
3’-UTR of miRNA target genes. 
The link between miRNA derangement and unpaired NK immunosurveillance makes miRNAs 
potential therapeutic targets [89]. MiRNA mimics or antimiRs can be used to increase or decrease the 
activity of miRNAs with tumor suppressive or oncogenic function. However, susceptibility to 
degradation in biological fluids and poor delivery to target sites might severely hamper the use of 
miRNAs in therapy. Chemical modifications of the miRNA backbone and the use of specific vehicles, 
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as nanoparticles or minicells, have been developed to confer stability to the miRNAs. Moreover, 
specific molecules, such as antibodies, can be conjugated to the miRNAs or to the vehicles to ensure 
an efficient and specific delivery. Avoiding toxicities and off-target effects are additional challenges 
for a miRNA-based therapeutic approach. 
In spite of these difficulties, two different phase I clinical trials treating cancer patients have 
been performed using miRNAs as therapeutic agents. The former study (NCT01829971) used 
miR-34 mimics encapsulated in lipid nanoparticles, without the association with specific targeting 
molecules, to treat patients affected by several solid tumors and hematological malignancies. 
Unfortunately, it was terminated due to immune related serious adverse events. In the latter study 
(NCT02369198), miR-16 mimics encapsulated in minicells targeted to EGFR-positive cancer cells 
by an anti-EGFR antibody have been used to treat patients with malignant pleural mesothelioma and 
non-small cell lung cancer. The study was regularly completed, establishing a dose of miRNA mimic 
which was well tolerated and accompanied by early signs of antitumor activity [90].  
Therefore, combination of targeted miRNA-based therapies with other therapeutic interventions 
represents a possible strategy to reduce tumor aggressiveness and to potentiate NK cell-mediated 
responses against cancer. 
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